Primary Central Nervous System Burkitt Lymphoma With Non-Immunoglobulin Heavy Chain Translocation in Right Ventricle: Case Report by Jiang, Ming et al.
PediatricHematologyandOncology, 28:454–458, 2011
Copyright C   Informa Healthcare USA, Inc.
ISSN: 0888-0018 print / 1521-0669 online
DOI: 10.3109/08880018.2011.566599
CASE REPORT
Primary Central Nervous System Burkitt Lymphoma
With Non-Immunoglobulin Heavy Chain
Translocation in Right Ventricle: Case Report
Ming Jiang, MD,1 Jiang Zhu, MD,1 Yong-song Guan, MD,1
and Li-qun Zou, MD2
1DepartmentofMedicalOncologyofCancerCenter,WestChinaHospital,Sichuan
University,Chengdu,P.R.China; 2DepartmentofMedicalOncologyofCancerCenter,West
ChinaHospital,SichuanUniversity,Chengdu,P.R.China;andStateKeyLaboratoryof
Biotherapy,WestChinaHospital,SichuanUniversity,Chengdu,P.R.China
Primary central nervous system Burkitt lymphoma (PCNSBL) is rare. Few cases of primary central
nervous system involvement with sporadic Burkitt lymphoma have been reported and its treat-
ment is now controversial. Here, the authors report a case of a 14-year-old boy suﬀering from
non-immunoglobulin heavy chain (IgH) translocation PCNSBL. To the authors’ knowledge, this
is the second case report describing primary Burkitt lymphoma involving cerebral ventricles. Af-
terreceivingcombinationtreatmentwithsurgery,stereotacticradiosurgery,andachemotherapy
regimen including high-dose methotrexate, the patient had a disease-free survival of 18 months.
Keywords Burkittlymphoma,combinationtherapy,primarycentralnervoussystemBurkittlym-
phoma, primary central nervous system lymphoma
Burkitt lymphoma (BL), rare and aggressive, is a form of B-cell non-Hodgkin lym-
phomawithatendencytodisseminatetothebonemarrowandmeninges[1].Central
nervoussysteminvolvementoccursinabout13%to17%ofadults[2]and12%ofchil-
dren with BL [3]. However, primary central nervous system Burkitt lymphoma (PC-
NSBL) is very rare. An extensive search of the literature showed that just a few cases
of PCNSBL have been reported in the past 30 years; only one reported that the tumor
located in the third ventricle and the left temporal horn [4].
Here,wepresentacasestudyabouta14-year-oldboywhocomplainedofintermit-
tent blunt headache caused by PCNSBL and had a long-term survival after combina-
tion therapy.
CASE REPORT
A 14-year-old boy complained of intermittent blunt headache without obvious cause
for 2 months. He had no vomiting, myasthenia, or hypoesthesia, no stool and urine
problems, and no fever, night sweats, or weight loss. On admission, he was found
to be in good physical condition with a Karnofsky performance score of 90, having
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FIGURE 1 Brain magnetic resonance imaging of the patient before treatment. (A) A 3.4 × 2.3 ×
2.4 cm mass in the anterior horn and body of the lateral ventricle with isointensity on the T1-
weighted axial image. (B) Sagittal view of the same fragment. (C) Mass with slight edema on the
T2-weighted image.
neither systemic nor neurological signs. Laboratory studies, including routine blood
tests, liver and kidney function, and serum lactate dehydrogenase (LDH), showed re-
sultswithinthenormalrange.Serumtestsforvirusinfections,includingthosecaused
by hepatitis B or C, human immunodeficiency virus (HIV), and Epstein-Barr virus
(EBV), were negative. Contrast-enhanced magnetic resonance imaging (MRI) of the
head detected a mass measuring 3.4 × 2.3 × 2.4 cm in size, isointense on T1- and
T2-weightedpulsesequences,affectingtherightanteriorhornandbodyofthelateral
ventriclewithringenhancement,withslightedemaofwhitematterintherightfrontal
and parietal lobes, the right basal ganglia, the external capsule, and the callosity, and
with left shift of the midline (Figure 1). A giant cell astrocytoma or ependymocytoma
was strongly suspected.
Surgery was preformed in December 2008 in our hospital and revealed a tumor,
solid in nature, firm, fish-shaped, and having an affluent blood supply. The tumor,
which was located in the right lateral ventricle, laterally closely adherent to the thala-
mus, was removed entirely. Postoperative hematoxylin and eosin (HE) staining of the
tumor tissue showed a characteristic starry-sky appearance and medium-sized lym-
phocytes. Immunohistochemistry demonstrated CD20+, CD10+, CD79a+,B C L - 6 +,
TdT−,M PO −,B C L- 2 −, CD3−, and Ki-67+ (>95%) (Figure 2). Fluorescent in situ hy-
bridization (FISH) analysis (c-myc dual-color break-apart rearrangement probe; Vy-
sis) found that MYC/IGH fusion probe was negative but MYC break-apart probe was
positiveforthetumorcells(Figure3).Owingtointerventricularforamenadhesionaf-
ter his surgery, the boy repeatedly had intracranial hypertension, so a ventriculoperi-
tonealshuntwasinserted2daysaftertheinitialoperation.Inordertoexcludesystemic
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FIGURE 2 Histology and immunohistochemistry. (A) Tumor tissue showed “starry-sky” appear-
ancewithmedium-sizedlymphocytes.Hematoxylinandeosin(HE)stain,originalmagnification×
200. (B) Positive CD79a on the membrane of the tumor cell (magnification × 400). (C) More than
95% of cells expressed Ki-67 (magnification × 400).
non-Hodgkin lymphoma, whole-body positron emission tomography/computed to-
mography (PET/CT) scan, bone marrow biopsy, and testicular ultrasound were per-
formed and no abnormal findings were obtained. Furthermore, spinal MRI and cere-
brospinalfluid(CSF)cytologicalexaminationyieldednormalresults.Thediagnosisof
PCNSBL was established.
Aftersurgery,thesymptomofheadachedisappearedandnonervousdisturbances
were observed. Gamma-knife therapy was carried out with border dose of 16 Gy, cov-
ered by a 45% isodose curve. Later chemotherapy was administered in a 21-day cycle
withamethotrexate(MTX)-basedprotocol(MTX3g/m2,day1,intravenous[i.v.];vin-
cristine 1.4 mg/m2, day 1, i.v.; prednisone 100 mg, days 1–5 per os [p.o.]; leucovorin
[CF]15mg/m2,every6hoursondays2,3,and4,i.v.).Atotalof6cyclesofchemother-
apy were delivered. No grade 2 or higher toxicities were found. Up until now, the pa-
tient has been disease-free for 18 months.
DISCUSSION
Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-
Hodgkin lymphoma developing in the brain, spinal cord, eyes, or leptomeninges
without evidence of systemic involvement [5]. Overall, PCNSL accounts for 0.5% to
FIGURE 3 A break-apart probe showed that tumor cells have c-myc translocations. (A) Tricolor
fusion probe for c-myc/IgH showed that tumor cells were negative for t(8;14), which (B) indicates
that the partner of myc was probably IgL or some other gene.
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2% of all primary brain tumors and 0.7% to 0.8% of all lymphomas. More than 90% of
PCNSLs are histologically classified as high-grade B-cell lymphomas, the remaining
cases are T-cell lymphomas (2% to 5%), mucosa-associated lymphoid tissue (MALT)
lymphoma,andothers[8].PCNSBLisrareandfewcaseshavebeenreported[4,6–18].
It often appears in cerebral hemisphere, basal ganglial, thalamus, and corpus callo-
sum lesions [19]. Until now, only one case has been reported to involve the cerebral
ventricles [18].
ThediagnosisofBurkittlymphomawasmadebytypical“starry-sky”appearancein
HEstainandimmunohistochemicalfindingsaccordingtotheWorldHealthOrganiza-
tionclassificationoftumorsoflymphoidtissues[20].AlthoughmostofthecasesofBL
havec-myctranslocations, upto10%ofcasesmaybec-mycnegative.Inabout80%of
casesthetranslocationisbetweenc-mycandtheIgHgenes,andintheremaining20%
the translocation is between c-myc and the non-IgH genes [21]. In our patient, FISH
analysisshowedthatc-myc/IgHfusionprobewasnegativebutc-mycapartprobewas
positive for the tumor cells, which implies the translocation is between c-myc and
some non-IgH genes.
Intensive short-course chemotherapy combining with intrathecal injection regi-
men was recommend to treat systemic BL [22], whereas for PCNSL, the high-dose
MTX-based chemotherapy regimen has been commonly used, which improves me-
dian disease-free and overall survival of up to 30 to 40 months from the survival of
12 to 18 months usually seen after using cranial radiotherapy (CRT) alone [23]. Some
studies use CRT plus high-dose MTX as first-line therapy [24], but more researches
recommendCRTaftersomeformofinitialchemotherapy,especiallytopatientsolder
than 60 years. Moreover, a pediatric series of PCNSL has reported that immunocom-
petent and immunodeficient children with PCNSL may be cured with chemotherapy
alonewithoutCRT[25].SotheroleandthetimingofCRTareintriguingyetcontrover-
sial.
To date, 14 sporadic PCNBL cases have been reported in the English literature [4,
6–18].Ofthe15cases,5areinvolvingchildren(includingours)[8,10,13,14],although
the treatment regimens were different, including surgery, radiotherapy, and systemic
and intrathecal chemotherapy. It seemed that the patients who received a combina-
tion management of MTX-based chemotherapy, radiotherapy, and/or surgery [9–11]
had much longer overall survival time than did those who only received surgery [6,
12]. However, the best regimens are still under discussion.
Our patient had an isolated brain mass <3.5 cm in diameter at the age of 14 years
and his spinal MRI and CSF cytology were negative. Thus we used gamma-knife ther-
apy instead of CRT to decrease the risk of CRT-related neuropsychological sequelae
[26]. During the whole 6 cycles of chemotherapy, no grade 2 or higher toxicities were
found. Up to now, the tumor has been in complete remission for 18 months and our
patient is attending school with no problems.
In summary, PCNSBL is a rare type of non-Hodgkin lymphoma, which has no
specific clinical manifestations and imaging features. Treatment is still controver-
sial. Our case report demonstrates that for isolated PCNSBL cases without spread to
cerebrospinalfluid,thecombinationtherapyofsurgery,gamma-knife,andhigh-dose
MTX-based protocol withoutintrathecal injection iseffective andacceptable forchil-
dren. This strategy reduced the risk of CRT and intrathecal injection and need to be
studied for more details.
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